Gravar-mail: A Phase III trial of 2 Years of Androgen Suppression (AS) and Radiation Therapy (RT) with or without Adjuvant Chemotherapy (CT) for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group (RTOG) Phase III Randomized Trial NRG Oncology RTOG 9902